C3 Complex by Sabinsa, used in Lipolife® Curcumin, was used in a newly published study on Non-Alcoholic Fatty Liver Disease (NAFLD), the most common chronic liver condition for which no approved pharmaceutical treatments currently exist.

NAFLD is a spectrum of disorders ranging from steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis of the liver.

It is also commonly associated with metabolic syndrome and cardiovascular diseases. It’s estimated up to 1 in every 3 people in the UK has early stages of NAFLD, where there are small amounts of fat in their liver.

The peer-reviewed paper published in the Journal of Cellular Biochemistry, 2019; 120: 15989-reports on the efficacy of C3 Complex combined with Sabinsa’s bioavailability enhancer BioPerine^® on NAFLD subjects in a randomised controlled parallel-group clinical trial.

The decrease in the severity of NAFLD in the subjects was gauged by hepatic sonography, and significant improvement was observed in several elevated liver function parameters such as ALT, ASP, and ALP in NAFLD subjects treated with the C3 Complex and BioPerine combination. NAFLD severity was reduced in a statistically significant way in the treatment group compared to the placebo group. No adverse effect on the hematological parameters were found, showing the safety of the ingredients.

Taking this powerhouse compound in a liposomal formula with proven increased absorption could be considered as majorly beneficial to those concerned by their own liver health.

The study may be accessed here: 15996 https://doi.org/10.1002/jcb.28877